










Image source: The Motley Fool.DATENov. 4, 2025 2:56 p.m. ETCALL PARTICIPANTSChairman, Chief Executive Officer, and President — R. Jeffrey BaillyChief Financial Officer — Ronald J. LatailleNeed a quote from a Motley Fool analyst? Email [email protected] Labor Disruption — More than 50% turnover in AJR Illinois direct labor workforce due to e-verify process caused a significant reduction in output, resulting in a $3 million decline in gross profit and operating income and a $0.28 reduction ...
San Francisco (www.aktiencheck.de) - Stryker-Aktienanalyse von Wells Fargo Advisors:Wells Fargo habe das Kursziel für die Aktie von Stryker Corp. (ISIN: US8636671013, WKN: 864952, Ticker-Symbol: SYK, NYSE-Symbol: SYK) von 452 auf 456 USD angehoben und das Rating "overweight" bestätigt. Die Bank verweise darauf, dass das Investorentreffen 2025 das Potenzial des Unternehmens für ein anhaltendes organisches Umsatzwachstum von 10% sowie ein zweistelliges EPS-Wachstum hervorgehoben habe. [mehr]
Bernstein reiterates Outperform rating on Stryker stock, cites growth outlook
The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.
Strykers Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.